Double-responsive hyaluronic acid-based prodrugs for efficient tumour targeting.
Boronates
Cancer
Field flow fractionation
Hyaluronic acid
Responsive release
Targeted drug delivery
Journal
Materials science & engineering. C, Materials for biological applications
ISSN: 1873-0191
Titre abrégé: Mater Sci Eng C Mater Biol Appl
Pays: Netherlands
ID NLM: 101484109
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
17
06
2021
revised:
30
09
2021
accepted:
01
10
2021
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Hyaluronic acid (HA)-based prodrugs bearing double-responsive (acid pH or oxidation) boronates of catechol-containing drugs were used to treat xenografted human prostate tumours (LNCaP) in SCID mice. The HA prodrugs accumulated significantly only in tumours (impressively, up to 40% of the injected dose after 24 h) and in liver, with negligible - actually anti-inflammatory - consequences in the latter. A quercetin-HA prodrug significantly slowed down tumour growth, in a dose-dependent fashion and with a much higher efficacy (up to 4 times) than equivalent doses of free quercetin. In short, boronated HA appears to be a very promising platform for targeted chemotherapy.
Identifiants
pubmed: 34857264
pii: S0928-4931(21)00615-9
doi: 10.1016/j.msec.2021.112475
pii:
doi:
Substances chimiques
Micelles
0
Prodrugs
0
Hyaluronic Acid
9004-61-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
112475Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.